-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

322.O3.6 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care Clinically Relevant Abstract

Symposia: Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Bleeding and Clotting, bleeding disorders, Biological therapies, Antibody Therapy, adult, Clinical Practice (Health Services and Quality), hemophilia, Bispecific Antibody Therapy, Non-Biological therapies, elderly, Clinical Research, health outcomes research, Genetic Disorders, health disparities research, Diversity, Equity, and Inclusion (DEI) , Coagulant Drugs, drug development, pediatric, Diseases, real-world evidence, Therapies, registries, VWD, Infusion, young adult , Study Population, Human
Saturday, December 9, 2023: 4:00 PM-5:30 PM
Room 30 (San Diego Convention Center)
Moderators:
Maissaa Janbain, MD, Tulane University School of Medicine and Patrick Ellsworth, MD, University of North Carolina at Chapel Hill
Disclosures:
Janbain: Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Speakers Bureau; Spark Therapeutics: Honoraria, Speakers Bureau; CSL Behring: Honoraria, Speakers Bureau; Genentech: Honoraria, Research Funding; Bayer: Honoraria, Speakers Bureau; Sobi: Honoraria; Octapharma: Honoraria; Biomarin: Honoraria. Ellsworth: Genentech: Consultancy, Honoraria; Novo Nordisk: Research Funding.
4:00 PM
283
Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence StudiesClinically Relevant Abstract

Miguel A. Escobar, M.D.1*, Qi Angela Fan2*, Ali G Mokdad, MD, PhD, MBA3*, Michael D. Tarantino, MD4, Benjamin Burgess, PhD5*, Emma Hawe, MSc5*, Maria Fernandez, PhD, MBA6* and Michael Bullano, PharmD7*

1Department of Medicine, Division of Hematology and Oncology, University of Texas Health Sciences Center Houston, Houston, TX
2Takeda Pharmaceuticals, U.S.A., Inc, Lexington, MA
3Takeda Pharmaceuticals, U.S.A., Cambridge, MA
4The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL
5RTI Health Solutions, Manchester, United Kingdom
6RTI Health Solutions, Research Triangle Park, NC
7Takeda Pharmaceuticals USA Inc, Lexington, MA
4:15 PM
284
The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Giancarlo Castaman1*, Aby Abraham, MD, DM2*, Pantep Angchaisuksiri3*, Laura Villarreal Martinez4*, Keiji Nogami5*, Jameela Sathar6*, Chunduo Shen7*, Jay Jay Thaung Zaw7* and Guy Young, MD8

1Center for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
2Department of Hematology, Christian Medical College, Vellore, Ranipet, India
3Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
4Dr. José Eleuterio González Monterrey University Hospital, Monterrey, Mexico
5Department of Pediatrics, Nara Medical University, Nara, Japan
6Department of Hematology, Ampang hospital, Selangor, Malaysia
7Novo Nordisk, Søborg, Denmark
8Children's Hospital Los Angeles, Los Angeles, CA
4:30 PM
285
Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis TrialClinically Relevant Abstract

Davide Matino, MD, MSc1*, Suchitra Acharya, MD2*, Andrew Palladino, MD3*, Eunhee Hwang, PhD3*, Regina McDonald4*, Carrie Turich Taylor, PhD, MHS4* and John Teeter, MD5*

1Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, ON, Canada
2Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, New Hyde Park, NY
3Pfizer Inc., Collegeville, PA
4Pfizer Inc., New York, NY
5Pfizer Inc., Groton, CT
4:45 PM
286
The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease

Yeu-Chin Chen, MD1, Chia-Yau Chang2*, Shin-Nan Cheng, MD, PhD3*, Shiue-Wei Lai, MD4* and Shu-Hsia Hu5*

1Hemophilia Care and Research Center, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
2Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan
3Hemophilia center, Department of Pediatrics, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan
4Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, TWN
5Hemophilia center, Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan
5:00 PM
287
Risk Factors for Joint Bleeding in Severe Hemophilia a and B: Analysis of the Community Counts Longitudinal Surveillance Cohort

Marilyn Manco-Johnson, MD1, Suchitra Acharya, MD2*, Sanjay Ahuja, MD3, Meera Chitlur, MD4, Divyaswathi Citla Sridhar, MD5, Stacey Fedewa, PhD, MPH6*, Daniel Isaac, DO, MSc7*, Roshni Kulkarni, MD8, Laura Schieve, PhD9*, Anjali A. Sharathkumar, MBBS, MD, MS10, Binh Le, PhD11* and Mike Soucie, PhD12*

1Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO
2Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, New Hyde Park, NY
3Case Western Reserve University, Cleveland, OH
4Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI
5Arkansas Children's Hospital, Little Rock, AR
6Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding & Clotting Disorders at Emory, Emory University, Atlanta, GA
7College of Human Medicine, Michigan State University, East Lansing, MI
8Centers for Bleeding and Clotting Disorders, Department of Pediatrics, Michigan State University, East Lansing, MI
9National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
10Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa Health Care, Iowa City, IA
11Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA
12Peers & Partners, Inc; Division of Blood Disorders, Centers For Disease Control and Prevention, Atlanta, GA
5:15 PM
288
Proactive Systematic Hemophilia Carrier Screening: A Step Towards Gender Equity in Hemophilia CareClinically Relevant Abstract

Evelien Krumb1*, Catherine Lambert, MD, PhD2*, An Van Damme, MD, PhD3 and Cedric R. Hermans, MD, MRCP, PhD3

1Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
2Cliniques universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, BEL
3Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, BEL
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>
*signifies non-member of ASH